In case you didn’t have the opportunity to attend the GRx+Biosims 2023 conference or were there and want to revisit the featured panel on nitrosamine impurities, here’s a quick recap and a link to the full Contract Pharma article, authored by Jennifer Leaming, Principal Consultant, Lachman Consultants. Four presentations were made by FDA representatives on […]
Lachman Consultants (Ireland) will participate at this year’s PDA Quality and Regulations Conference in Antwerp, Belgium, November 7 – 8. The two-day in-person event will cover a wide range of topics related to regulatory and industry best practices, with a particular emphasis on addressing shortages and enhancing supply chain resilience. Lachman Consultants (Ireland) will be […]
Join us September 28th, 2023, at 10:00 AM EDT for A Lachman Learning Experience. Where are you on your Annex 1 journey? Have you created a measurable plan for progress? Assess your current position and start making plans for the future by attending this highly informative and valuable webinar. Join Lachman Consultants’ Executive Director Keith […]
Join Lachman Consultants in Washington, DC, Sep 18-20, for the 2023 PDA/FDA Joint Regulatory Conference. Themed “CGMP: Quality Through Science and Innovation,” this year’s event will delve into the pivotal role effective quality systems play in ensuring an ongoing state of control throughout the product lifecycle. As a Silver Sponsor at this year’s event, Lachman […]
Unless you’ve been living under a (pharmaceutical) rock, you are aware of the struggle that both FDA and industry are having with Nitrosamines impurities in pharmaceutical products. As a reminder, APIs are at risk of forming nitrosamine drug substance-related impurities (NDSRIs) when they contain secondary amines or dimethyl tertiary amines. We have published many blogs […]
In a complete supply chain, one site’s lag measure is another site’s lead measure. As important as data integrity is to product quality decisions at the site, data risks in the supply chain can affect availability of product to patients. As mentioned in a previous Lachman blog (here), drug shortages are the preeminent risk for […]
